Campos Carrascosa, Lucia http://orcid.org/0000-0003-3321-7153
van Beek, Adriaan A http://orcid.org/0000-0003-0786-1682
de Ruiter, Valeska
Doukas, Michail
Wei, Jie
Fisher, Timothy S
Ching, Keith
Yang, Wenjing
van Loon, Karlijn
Boor, Patrick P C
Rakké, Yannick S
Noordam, Lisanne
Doornebosch, Pascal
Grünhagen, Dirk
Verhoef, Kees
Polak, Wojciech G
IJzermans, Jan N M
Ni, Irene
Yeung, Yik Andy
Salek-Ardakani, Shahram http://orcid.org/0000-0002-2336-8452
Sprengers, Dave
Kwekkeboom, Jaap
Clinical trials referenced in this document:
Documents that mention this clinical trial
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells
https://doi.org/10.1136/jitc-2020-000816
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
https://doi.org/10.1136/jitc-2021-002591
P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort
https://doi.org/10.1136/lba2019.14
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005471
Documents that mention this clinical trial
FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells
https://doi.org/10.1136/jitc-2020-000816
P860 Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort
https://doi.org/10.1136/lba2019.14
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
https://doi.org/10.1136/jitc-2021-002591
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2022-005471
Funding for this research was provided by:
Pfizer
Erasmus Medisch Centrum